These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34508869)

  • 1. Severity of Hepatitis B Relapse After Cessation of Nucleos(t)ide Analog: Need a Closer Look!
    Jindal A
    Clin Gastroenterol Hepatol; 2022 Aug; 20(8):1885-1886. PubMed ID: 34508869
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter regarding "Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation".
    Liaw YF
    Clin Mol Hepatol; 2024 Apr; 30(2):269-271. PubMed ID: 38295765
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-HBc level predicting virological relapse after stopping nucleos(t)ide analogue in chronic hepatitis B.
    Huang CB; Su TH; Kao JH
    Liver Int; 2023 Apr; 43(4):947-948. PubMed ID: 36732913
    [No Abstract]   [Full Text] [Related]  

  • 4. A comment on "A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B".
    Wan YM; Wu HM; Huang SQ; Li HY; Yin HJ
    J Hepatol; 2024 May; 80(5):e229-e230. PubMed ID: 37572795
    [No Abstract]   [Full Text] [Related]  

  • 5. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
    Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
    J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reply to: "A comment on `A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B'".
    van Bömmel F; Berg T
    J Hepatol; 2024 May; 80(5):e230-e231. PubMed ID: 38110010
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B.
    Fan R; Peng J; Xie Q; Tan D; Xu M; Niu J; Wang H; Ren H; Chen X; Wang M; Sheng J; Tang H; Bai X; Wu Y; Zhou B; Sun J; Hou J;
    J Infect Dis; 2020 Jul; 222(4):611-618. PubMed ID: 32211776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes.
    Van Hees S; Bourgeois S; Van Vlierberghe H; Sersté T; Francque S; Michielsen P; Sprengers D; Reynaert H; Henrion J; Negrin Dastis S; Delwaide J; Lasser L; Decaestecker J; Orlent H; Janssens F; Robaeys G; Colle I; Stärkel P; Moreno C; Nevens F; Vanwolleghem T;
    Aliment Pharmacol Ther; 2018 Apr; 47(8):1170-1180. PubMed ID: 29498078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B.
    van Bömmel F; Berg T
    Liver Int; 2018 Feb; 38 Suppl 1():90-96. PubMed ID: 29427489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained off-treatment viral control is associated with high hepatitis B surface antigen seroclearance rates in Caucasian patients with nucleos(t)ide analogue-induced HBeAg seroconversion.
    Van Hees S; Chi H; Hansen B; Bourgeois S; Van Vlierberghe H; Sersté T; Francque S; Wong D; Sprengers D; Moreno C; Nevens F; Janssen HLA; Vanwolleghem T
    J Viral Hepat; 2019 Jun; 26(6):766-769. PubMed ID: 30801868
    [No Abstract]   [Full Text] [Related]  

  • 12. Increased intrahepatic quasispecies heterogeneity correlates with off-treatment sustained response to nucleos(t)ide analogues in e antigen-positive chronic hepatitis B patients.
    Chen L; Gan QR; Zhang DQ; Yao LF; Lin RS; Li Q; Lin MH; Yu DM; Zhang XX; Pan C
    Clin Microbiol Infect; 2016 Feb; 22(2):201-207. PubMed ID: 26493847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Seroreversion and Acute Decompensation in Chronic Hepatitis B after Discontinuation of Oral Nucleotide Analog in the Patients Achieving HBsAg Loss].
    Cho HJ; Shin SK; Kwon OS; Kim JH; Kim YS
    Korean J Gastroenterol; 2020 Nov; 76(5):256-260. PubMed ID: 33234774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of relapse after cessation of nucleos(t)ide analog treatment in HBeAg-negative chronic hepatitis B patients: A meta-analysis.
    Liu Y; Jia M; Wu S; Jiang W; Feng Y
    Int J Infect Dis; 2019 Sep; 86():201-207. PubMed ID: 31394205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
    Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL
    Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of nucleos(t)ide analog intervention in patients with preventive or on-demand therapy for hepatitis B virus reactivation.
    Tamori A; Kimura K; Kioka K; Enomoto H; Odagiri N; Kozuka R; Uchida-Kobayashi S; Enomoto M; Kawada N; Mizokami M
    J Med Virol; 2021 Jun; 93(6):3679-3687. PubMed ID: 32940921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg-Negative CHB.
    Wübbolding M; Lopez Alfonso JC; Lin CY; Binder S; Falk C; Debarry J; Gineste P; Kraft ARM; Chien RN; Maasoumy B; Wedemeyer H; Jeng WJ; Meyer Hermann M; Cornberg M; Höner Zu Siederdissen C
    Hepatol Commun; 2021 Jan; 5(1):97-111. PubMed ID: 33437904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
    Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C
    Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse.
    Xu WX; Zhang Q; Zhu X; Lin CS; Chen YM; Deng H; Mei YY; Zhao ZX; Xie DY; Gao ZL; Xie C; Peng L
    Can J Gastroenterol Hepatol; 2018; 2018():1817680. PubMed ID: 29862225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Keystone to Secure Safety After Stopping Nucleos(t)ide Analogue Therapy in Chronic Hepatitis B Patients.
    Liu YC; Jeng WJ; Chen CH
    Clin Gastroenterol Hepatol; 2022 Aug; 20(8):1890-1891. PubMed ID: 34583016
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.